+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Axial Spondyloarthritis Market - Global Forecast to 2030- Product Image
Axial Spondyloarthritis Market - Global Forecast to 2030- Product Image
Sale

Axial Spondyloarthritis Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5924702
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Axial Spondyloarthritis Market grew from USD 5.68 billion in 2024 to USD 6.12 billion in 2025. It is expected to continue growing at a CAGR of 7.54%, reaching USD 8.79 billion by 2030.

Axial spondyloarthritis represents a group of chronic inflammatory disorders targeting the spine and sacroiliac joints, manifesting as persistent back pain, stiffness and progressive loss of mobility. This condition encompasses two distinct forms: non-radiographic axial spondyloarthritis, which often relies on advanced biomarker assays and MRI imaging for early detection, and radiographic axial spondyloarthritis-commonly known as ankylosing spondylitis-where structural changes become visible on X-rays. The rising prevalence of these conditions, particularly among young adults, imposes a growing burden on healthcare systems and patient quality of life. As therapeutic innovation accelerates, stakeholders across diagnostics, pharmaceuticals and care delivery must navigate a highly segmented landscape shaped by disease phenotype, treatment modality and end-user environment. Moreover, the convergence of novel biologics, small molecules and digital health platforms is transforming clinical pathways. Given this dynamic environment, a comprehensive understanding of market drivers, regulatory headwinds and stakeholder priorities is critical for decision-makers seeking to optimize patient outcomes and commercial success.

Transformative Shifts in the Axial Spondyloarthritis Landscape

Over the past decade, diagnostic and therapeutic paradigms in axial spondyloarthritis have undergone profound transformation. Cutting-edge biomarker assays now complement MRI diagnostics, enabling earlier identification of non-radiographic forms. Concurrently, targeted therapies have expanded beyond TNF inhibitors to include IL-17 blockers and Janus kinase inhibitors, reshaping treatment algorithms. Digital health solutions-ranging from telemedicine consultations to remote physiotherapy monitoring-have further empowered patient-centric care, while real-world evidence platforms accelerate post-launch safety and efficacy assessments. Regulatory frameworks are evolving in tandem, with expedited pathways for breakthrough therapies and adaptive trial designs encouraging innovation in biosimilars and gene therapy. Global supply chains are also being optimized through strategic alliances, ensuring uninterrupted access to complex biologics. As a result, the market is shifting from a one-size-fits-all approach to a precision medicine model, where tailored interventions and integrated care pathways deliver superior clinical and economic value.

Cumulative Impact of U.S. Tariffs on the 2025 Treatment Supply Chain

The implementation of new U.S. import tariffs in 2025 has introduced a complex set of challenges and opportunities across the axial spondyloarthritis ecosystem. Tariff escalations on critical biologic reagents, diagnostic imaging equipment and specialized infusion supplies have elevated production and logistics costs for manufacturers and distributors. In response, several pharmaceutical and device companies have reevaluated their global sourcing strategies, forging local manufacturing partnerships to mitigate duty exposure. Payers and providers are recalibrating formulary decisions to balance cost pressures with the clinical necessity of advanced therapies, which may lead to increased emphasis on value-based contracting and outcome-driven reimbursement models. At the same time, research institutions are adapting grant and collaboration structures to account for higher import expenses, potentially influencing the pace of clinical trials and biomarker discovery programs. While short-term cost inflation poses a risk to patient access, the tariff environment also encourages greater supply chain resilience and regional self-sufficiency over the long term.

Comprehensive Segmentation Insights Across Clinical and Commercial Axes

A nuanced segmentation analysis reveals that stakeholders must tailor strategies across multiple dimensions to effectively address patient needs and market dynamics. Disease-type segmentation distinguishes non-radiographic axial spondyloarthritis from radiographic ankylosing spondylitis, with the former relying on biomarker diagnosis protocols and MRI diagnostics to identify early inflammation, and the latter stratified by HLA-B27 genetic status-positive or negative-to guide long-term management plans. Treatment-type segmentation differentiates non-pharmacological options such as structured exercise programs, lifestyle modifications and targeted physical therapy from pharmacological interventions that span future sub-segmentations including biosimilars and gene therapy alongside established IL-17 inhibitors, Janus kinase inhibitors, NSAIDs and TNF inhibitors. End-user segmentation captures the roles of hospitals and clinics-both private and public-patient organizations ranging from local support groups to national advocacy bodies, and research institutions comprising academic centers and clinical research organizations. Age-group segmentation categorizes adult, geriatric and pediatric populations, ensuring age-appropriate diagnostic and therapeutic pathways. Severity-level segmentation spans mild and moderate presentations, while severe cases further divide into mobility-impaired and spinal fusion-related cohorts, necessitating specialized care. Drug-formulation segmentation addresses injections-professionally administered or self-injected-intravenous infusions and oral tablets, each with unique patient adherence and distribution considerations. Clinical-settings segmentation encompasses in-patient and out-patient care models, and channel-of-distribution segmentation differentiates agency distribution, direct sales channels and pharmacy networks, with pharmacies sub-segmented into online and retail outlets. By leveraging these segmentation insights, manufacturers, payers and care providers can refine product positioning, optimize resource allocation and deliver personalized patient journeys.

Key Regional Insights Influencing Access and Adoption

Regional dynamics play a pivotal role in shaping access, adoption and innovation across axial spondyloarthritis. In the Americas, robust reimbursement frameworks and high health-technology investment propel rapid uptake of advanced biologics, while emerging telehealth platforms are expanding rural access to specialist care. Within Europe, Middle East & Africa, heterogeneous regulatory landscapes drive varied biosimilar penetration rates, with Western Europe prioritizing cost-containment and MEA regions investing in diagnostic infrastructure to address underdiagnosis. Across the Asia-Pacific, burgeoning patient awareness programs and government initiatives are accelerating early screening efforts, supported by local manufacturing partnerships that reduce overall treatment costs. Collaborative research networks spanning these regions are also enabling multi-center clinical studies, enhancing the evidence base for novel therapies. As stakeholder ecosystems mature, cross-regional learnings and harmonized regulatory approaches will be instrumental in broadening global access to life-changing interventions.

Key Company Strategies and Competitive Dynamics

Leading biopharmaceutical and diagnostics companies are strategically positioning their portfolios to capitalize on evolving patient needs and regulatory incentives. Abbott Laboratories is advancing point-of-care biomarker assays to streamline early detection, while AbbVie Inc. and Pfizer Inc. continue to solidify their leadership in IL-17 and JAK inhibitor segments through expanded label indications and real-world evidence integration. Amgen Inc. is exploring innovative small-molecule approaches, and Eli Lilly and Company is fast-tracking JAK inhibitor trials to address unmet safety and efficacy benchmarks. Galapagos NV is pioneering novel anti-inflammatory mechanisms, complemented by Inmagene Biopharmaceuticals’ focus on next-generation biologics. Johnson & Johnson Services, Inc. is enhancing patient support programs to improve long-term adherence, and Merck & Co., Inc. is leveraging diagnostic partnerships to refine patient stratification. Novartis AG is driving gene therapy research, while UCB S.A. is intensifying efforts in personalized treatment algorithms. These strategic initiatives underscore a competitive landscape where collaboration, pipeline diversity and patient-centric innovation define market leadership.

Actionable Recommendations for Industry Leaders

Industry leaders should pivot toward integrated solutions that align diagnostic precision with targeted therapy deployment. Investing in advanced biomarker and imaging platforms will accelerate early diagnosis and treatment initiation. Strengthening local manufacturing and distribution networks can mitigate tariff-related cost increases and improve supply chain agility. Engaging patient organizations and research institutions in co-development initiatives enhances real-world evidence generation and fosters community trust. Prioritizing value-based contracting and outcome-focused reimbursement models can secure payer support while maintaining affordability. Expanding digital health offerings-including telemedicine, remote monitoring and patient engagement apps-will elevate adherence and satisfaction. Allocating R&D resources to biosimilar and gene therapy platforms ensures long-term pipeline sustainability. Finally, forging cross-sector partnerships with regulatory bodies and academic consortia will expedite innovation and harmonize global standards.

Conclusion: Charting a Collaborative Path Forward

Navigating the complex terrain of axial spondyloarthritis requires a holistic approach that balances innovation, access and sustainability. By integrating advanced diagnostics with next-generation therapeutics, stakeholders can unlock personalized care pathways that improve patient outcomes and reduce long-term costs. Alignment between manufacturers, payers, providers and patient communities will drive the successful adoption of emerging modalities, from biosimilars to gene therapy. Moreover, resilient supply chain strategies and adaptive commercial models will safeguard against policy shifts and economic fluctuations. As data ecosystems mature, leveraging real-world evidence and digital engagement tools will become indispensable. Ultimately, a forward-looking, collaborative mindset will position organizations at the vanguard of care delivery, ensuring that breakthroughs in axial spondyloarthritis translate into tangible health gains.

Market Segmentation & Coverage

This research report categorizes the Axial Spondyloarthritis Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Non-Radiographic Axial Spondyloarthritis
    • Biomarker Diagnosis
    • MRI Diagnosis
  • Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)
    • HLA-B27 Negative
    • HLA-B27 Positive
  • Non-Pharmacological Treatment
    • Exercise
    • Lifestyle Modifications
    • Physical Therapy
  • Pharmacological Treatment
    • Future Sub-Segmentations
      • Biosimilars
      • Gene Therapy
    • IL-17 Inhibitors
    • Janus kinase (JAK) Inhibitors
    • NSAIDs
    • TNF Inhibitors
  • Hospitals & Clinics
    • Private Clinics
    • Public Hospitals
  • Patient Organizations
    • Local Support Groups
    • National Organizations
  • Research Institutions
    • Academic Institutions
    • Clinical Research Organizations (CROs)
  • Adult
  • Geriatric
  • Pediatric
  • Mild
  • Moderate
  • Severe
    • Mobility Impaired
    • Spinal Fusion-Related
  • Injections
    • Professional Administration
    • Self-Administered
  • Intravenous Infusion
  • Tablets
  • In-Patient
  • Out-Patient
  • Agency Distribution
  • Direct Sales
  • Pharmacies
    • Online Pharmacies
    • Retail Pharmacies

This research report categorizes the Axial Spondyloarthritis Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Axial Spondyloarthritis Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Galapagos NV
  • Inmagene Biopharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • UCB S.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Axial Spondyloarthritis Market, by Disease Type
8.1. Introduction
8.2. Non-Radiographic Axial Spondyloarthritis
8.2.1. Biomarker Diagnosis
8.2.2. MRI Diagnosis
8.3. Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)
8.3.1. HLA-B27 Negative
8.3.2. HLA-B27 Positive
9. Axial Spondyloarthritis Market, by Treatment Type
9.1. Introduction
9.2. Non-Pharmacological Treatment
9.2.1. Exercise
9.2.2. Lifestyle Modifications
9.2.3. Physical Therapy
9.3. Pharmacological Treatment
9.3.1. Future Sub-Segmentations
9.3.1.1. Biosimilars
9.3.1.2. Gene Therapy
9.3.2. IL-17 Inhibitors
9.3.3. Janus kinase (JAK) Inhibitors
9.3.4. NSAIDs
9.3.5. TNF Inhibitors
10. Axial Spondyloarthritis Market, by End User
10.1. Introduction
10.2. Hospitals & Clinics
10.2.1. Private Clinics
10.2.2. Public Hospitals
10.3. Patient Organizations
10.3.1. Local Support Groups
10.3.2. National Organizations
10.4. Research Institutions
10.4.1. Academic Institutions
10.4.2. Clinical Research Organizations (CROs)
11. Axial Spondyloarthritis Market, by Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Axial Spondyloarthritis Market, by Severity Level
12.1. Introduction
12.2. Mild
12.3. Moderate
12.4. Severe
12.4.1. Mobility Impaired
12.4.2. Spinal Fusion-Related
13. Axial Spondyloarthritis Market, by Drug Formulation
13.1. Introduction
13.2. Injections
13.2.1. Professional Administration
13.2.2. Self-Administered
13.3. Intravenous Infusion
13.4. Tablets
14. Axial Spondyloarthritis Market, by Clinical Settings
14.1. Introduction
14.2. In-Patient
14.3. Out-Patient
15. Axial Spondyloarthritis Market, by Channel Of Distribution
15.1. Introduction
15.2. Agency Distribution
15.3. Direct Sales
15.4. Pharmacies
15.4.1. Online Pharmacies
15.4.2. Retail Pharmacies
16. Americas Axial Spondyloarthritis Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Axial Spondyloarthritis Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Axial Spondyloarthritis Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Abbott Laboratories
19.3.2. AbbVie Inc.
19.3.3. Amgen Inc.
19.3.4. Eli Lilly and Company
19.3.5. Galapagos NV
19.3.6. Inmagene Biopharmaceuticals
19.3.7. Johnson & Johnson Services, Inc.
19.3.8. Merck & Co., Inc.
19.3.9. Novartis AG
19.3.10. Pfizer Inc.
19.3.11. UCB S.A.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. AXIAL SPONDYLOARTHRITIS MARKET MULTI-CURRENCY
FIGURE 2. AXIAL SPONDYLOARTHRITIS MARKET MULTI-LANGUAGE
FIGURE 3. AXIAL SPONDYLOARTHRITIS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERITY LEVEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERITY LEVEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICAL SETTINGS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICAL SETTINGS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2024 VS 2030 (%)
FIGURE 22. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. AXIAL SPONDYLOARTHRITIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY BIOMARKER DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY MRI DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (ANKYLOSING SPONDYLITIS), BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HLA-B27 NEGATIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HLA-B27 POSITIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (ANKYLOSING SPONDYLITIS), 2018-2030 (USD MILLION)
TABLE 15. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY EXERCISE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY LIFESTYLE MODIFICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FUTURE SUB-SEGMENTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FUTURE SUB-SEGMENTATIONS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JANUS KINASE (JAK) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PATIENT ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY LOCAL SUPPORT GROUPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NATIONAL ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PATIENT ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY MOBILITY IMPAIRED, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPINAL FUSION-RELATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PROFESSIONAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SELF-ADMINISTERED, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICAL SETTINGS, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IN-PATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY OUT-PATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY AGENCY DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (ANKYLOSING SPONDYLITIS), 2018-2030 (USD MILLION)
TABLE 75. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FUTURE SUB-SEGMENTATIONS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PATIENT ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICAL SETTINGS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (ANKYLOSING SPONDYLITIS), 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FUTURE SUB-SEGMENTATIONS, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PATIENT ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICAL SETTINGS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (ANKYLOSING SPONDYLITIS), 2018-2030 (USD MILLION)
TABLE 114. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FUTURE SUB-SEGMENTATIONS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PATIENT ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICAL SETTINGS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 130. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 131. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 132. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (ANKYLOSING SPONDYLITIS), 2018-2030 (USD MILLION)
TABLE 133. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 134. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 135. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 136. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FUTURE SUB-SEGMENTATIONS, 2018-2030 (USD MILLION)
TABLE 137. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 139. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PATIENT ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 140. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 141. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 142. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 143. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 144. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 145. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 146. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICAL SETTINGS, 2018-2030 (USD MILLION)
TABLE 147. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 148. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 149. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 150. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 151. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (ANKYLOSING SPONDYLITIS), 2018-2030 (USD MILLION)
TABLE 152. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 153. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 154. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 155. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FUTURE SUB-SEGMENTATIONS, 2018-2030 (USD MILLION)
TABLE 156. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 158. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PATIENT ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 159. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 160. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 162. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 163. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 164. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 165. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICAL SETTINGS, 2018-2030 (USD MILLION)
TABLE 166. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 167. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (ANKYLOSING SPONDYLITIS), 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FUTURE SUB-SEGMENTATIONS, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PATIENT ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICAL SETTINGS, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (ANKYLOSING SPONDYLITIS), 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FUTURE SUB-SEGMENTATIONS, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PATIENT ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICAL SETTINGS, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (ANKYLOSING SPONDYLITIS), 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FUTURE SUB-SEGMENTATIONS, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 217. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PATIENT ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 219. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 220. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 221. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 222. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 223. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICAL SETTINGS, 2018-2030 (USD MILLION)
TABLE 225. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 227. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 228. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 229. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (ANKYLOSING SPONDYLITIS), 2018-2030 (USD MILLION)
TABLE 230. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 231. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 232. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 233. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FUTURE SUB-SEGMENTATIONS, 2018-2030 (USD MILLION)
TABLE 234. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 236. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PATIENT ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 237. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 238. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 239. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 240. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 241. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 242. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 243. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICAL SETTINGS, 2018-2030 (USD MILLION)
TABLE 244. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 245. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 246. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 247. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 248. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (ANKYLOSING SPONDYLITIS), 2018-2030 (USD MILLION)
TABLE 249. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 250. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 251. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 252. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FUTURE SUB-SEGMENTATIONS, 2018-2030 (USD MILLION)
TABLE 253. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 255. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PATIENT ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 256. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 257. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 258. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 259. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 260. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 261. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 262. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICAL SETTINGS, 2018-2030 (USD MILLION)
TABLE 263. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 264. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 265. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 266. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 267. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (ANKYLOSING SPONDYLITIS), 2018-2030 (USD MILLION)
TABLE 268. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 269. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FUTURE SUB-SEGMENTATIONS, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PATIENT ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICAL SETTINGS, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 283. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 284. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 285. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 286. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (ANKYLOSING SPONDYLITIS), 2018-2030 (USD MILLION)
TABLE 287. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 288. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 289. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 290. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FUTURE SUB-SEGMENTATIONS, 2018-2030 (USD MILLION)
TABLE 291. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 293. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PATIENT ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 294. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 295. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 296. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 297. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 298. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 299. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 300. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICAL SETTINGS, 2018-2030 (USD MILLION)
TABLE 301. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CHANNEL OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 302. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 305. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (ANKYLOSING SPONDYLITIS), 2018-2030 (USD MILLION)
TABLE 306. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 307. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 308. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 309. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FUTURE SUB-SEGMENTATIONS, 2018-2030 (USD MILLION)
TABLE 310. MALAYSIA AXIAL SPOND

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Galapagos NV
  • Inmagene Biopharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • UCB S.A.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Axial Spondyloarthritis - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Axial Spondyloarthritis - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 231 Pages
  • Global
From
Axial Spondyloarthritis (AXSPA) Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Axial Spondyloarthritis (AXSPA) Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Axial Spondyloarthritis (AxSpA) Market Report 2025 - Product Image

Axial Spondyloarthritis (AxSpA) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Non-Radiographic Axial Spondyloarthritis (nrAxSpA) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Non-Radiographic Axial Spondyloarthritis (nrAxSpA) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Axial Spondyloarthritis Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Axial Spondyloarthritis Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 83 Pages
  • Global
From

About the Axial Spondyloarthritis Drug Market

Axial Spondyloarthritis (axSpA) is a type of inflammatory arthritis that affects the spine and sacroiliac joints. It is a chronic, progressive condition that can cause pain, stiffness, and swelling in the affected areas. Immune Disorders Drugs are used to treat axSpA, as they help to reduce inflammation and pain. These drugs can be taken orally, injected, or infused, depending on the severity of the condition. Commonly used drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologic agents, and corticosteroids. The Axial Spondyloarthritis Drug market is a rapidly growing segment of the Immune Disorders Drugs market. It is driven by the increasing prevalence of axSpA, as well as the development of new drugs and treatments. Companies in the market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.